Burixafor - TaiGen Biotechnology

Drug Profile

Burixafor - TaiGen Biotechnology

Alternative Names: TG-0054

Latest Information Update: 24 Jan 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator TaiGen Biotechnology
  • Class Anti-ischaemics; Eye disorder therapies; Small molecules
  • Mechanism of Action CXCR4 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Stem cell mobilisation
  • No development reported Age-related macular degeneration; Diabetic retinopathy

Most Recent Events

  • 24 Jun 2018 Biomarkers information updated
  • 24 Jan 2018 Burixafor is still in phase I/II trials for Stem cell mobilisation (for chemosensitisation in haematological malignancies) in China (IV) (TaiGen Biotechnology pipeline, January 2018)
  • 24 Jan 2018 Burixafor is still in phase II trials for Stem cell mobilisation in USA (IV) (TaiGen Biotechnology pipeline, January 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top